MAFG-AS1: MAFG-AS1 is a long non-coding RNA (lncRNA) that has been reported to be upregulated and play an oncogene role in several common carcinomas, including colorectal cancer [PMC8799265], breast cancer [PMC7655217], lung cancer [PMC8799265], hepatocellular carcinoma [PMC8799265], and gastric cancer [PMC8799265]. However, its role in bladder cancer remains unclear [PMC8799265]. In prostate cancer, MAFG-AS1 expression was found to be overexpressed [PMC9389335]. Furthermore, MAFG-AS1 was investigated for its ability to increase tamoxifen resistance in native T47D cells through overexpression [PMC7655217]. In a study on esophageal squamous cell carcinoma (ESCC), the expression of MAFG-AS1 was examined in ESCC tissues and cell lines. The study also investigated the effects of MAFG-AS1 on the proliferation, migration, invasion, and aerobic glycolysis of ESCC cells by modulating the miR-765/PDX1 axis [PMC7415466]. Overall, MAFG-AS1 has been implicated in various types of cancers and has been shown to have oncogenic properties. However, its specific role in bladder cancer is still unclear [PMC8799265]. In prostate cancer and ESCC specifically, MAFG-AS1 expression has been found to be upregulated [PMC9389335] [PMC7415466]. Additionally, MAFG-AS1 has been shown to contribute to tamoxifen resistance in breast cancer cells [PMC7655217]. These findings highlight the potential significance of MAFG-AS1 as a therapeutic target or biomarker for various cancers.